Oncobax AK
Alternative Names: Oncobax®-AK; Oncobax®-AK - EverImmuneLatest Information Update: 06 Jun 2025
At a glance
- Originator EverImmune
- Class Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 19 May 2023 Oncobax-AK is available for licensing as of 19 May 2023. https://www.everimmune.net/partners (EverImmune website, May 2023)
- 01 Oct 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) in Belgium (PO) (NCT05865730)